{"protocolSection": {"identificationModule": {"nctId": "NCT01365091", "orgStudyIdInfo": {"id": "CV181-162"}, "organization": {"fullName": "AstraZeneca", "class": "INDUSTRY"}, "briefTitle": "Bioequivalence Study of Fixed-dose Combinations and Coadministered Individual Tablets of Saxagliptin/Metformin-Brazil", "officialTitle": "Bioequivalence Study of Fixed Dose Combinations of Saxagliptin/Metformin Extended Release (XR) Relative to Co-administration of the Individual Components in Healthy Subjects in the Fasted and Fed States"}, "statusModule": {"statusVerifiedDate": "2015-04", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2011-06"}, "primaryCompletionDateStruct": {"date": "2011-11", "type": "ACTUAL"}, "completionDateStruct": {"date": "2011-11", "type": "ACTUAL"}, "studyFirstSubmitDate": "2011-05-16", "studyFirstSubmitQcDate": "2011-06-01", "studyFirstPostDateStruct": {"date": "2011-06-03", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2013-03-20", "resultsFirstSubmitQcDate": "2013-08-16", "resultsFirstPostDateStruct": {"date": "2013-08-19", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2015-04-21", "lastUpdatePostDateStruct": {"date": "2015-05-08", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "AstraZeneca", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "To demonstrate the bioequivalence of saxagliptin and metformin in a saxagliptin, 5-mg/metformin extended-release (XR), 500-mg, fixed-dose combination (FDC) tablet with saxagliptin, 5-mg and metformin, 500-mg XR tablets administered together in both the fasted and fed states. In addition, to demonstrate the bioequivalence of saxagliptin and metformin in a saxagliptin, 5-mg/metformin XR, 1000-mg, FDC tablet with saxagliptin, 5-mg and metformin, 1000-mg XR tablets administered together in both the fasted and fed states."}, "conditionsModule": {"conditions": ["Type 2 Diabetes Mellitus"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "CROSSOVER", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 112, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Arm 1: Treatments A,B/B,A", "type": "EXPERIMENTAL", "description": "Period 1: Participants received a single oral dose of saxagliptin, 5 mg/metformin, 500 mg fixed-dose combination (FDC) in the fasted state (Treatment A), followed by a washout period of at least 7 days. Then, participants received single oral doses of saxagliptin, 5-mg, and metformin extended-release (XR), 500-mg, tablets together in the fasted state (Treatment B). Followed by a washout period of at least 4 days.\n\nPeriod 2: Participants received single oral doses of saxagliptin, 5-mg and metformin XR, 500-mg tablets together in the fasted state (Treatment B), followed by a washout period of at least 7 days. Then, participants received a single oral dose of saxagliptin, 5 mg/metformin, 500 mg FDC, in the fasted state (Treatment A).", "interventionNames": ["Drug: Saxagliptin/metformin fixed-dose combination (FDC)", "Drug: Saxagliptin", "Drug: Metformin extended-release (XR)"]}, {"label": "Arm 2: Treatments C,D/D,C", "type": "EXPERIMENTAL", "description": "Period 1: Participants received a single oral dose of saxagliptin, 5 mg/metformin, 500 mg fixed-dose combination (FDC), in the fed state (Treatment C), followed by a washout period of at least 7 days. Then, participants received a single oral dose of saxagliptin, 5-mg, and metformin extended-release (XR), 500-mg tablets together in the fed state (Treatment D). Followed by a washout period of at least 4 days.\n\nPeriod 2: Participants received a single oral dose of saxagliptin, 5-mg and metforminXR, 500-mg tablets together in the fed state (Treatment D), followed by a washout period of at least 7 days. Participants received a single oral dose of saxagliptin, 5 mg/metformin, 500 mg FDC, in the fed state (Treatment C).", "interventionNames": ["Drug: Saxagliptin/metformin fixed-dose combination (FDC)", "Drug: Saxagliptin", "Drug: Metformin extended-release (XR)"]}, {"label": "Arm 3: Treatments E, F/F,E", "type": "EXPERIMENTAL", "description": "Period 1: Participants received a single oral dose of saxagliptin, 5 mg/metformin, 1000 mg fixed-dose combination (FDC), in the fasted state (Treatment E), followed by a washout period of at least 7 days. Participants received single oral doses of saxagliptin, 5-mg and metformin extended-release (XR), 1000-mg tablets together in the fasted state (Treatment F). Followed by a washout period of at least 4 days.\n\nPeriod 2: Participants received single oral doses of saxagliptin, 5- mg and metformin XR, 1000-mg tablets together in the fasted state (Treatment F), followed by a washout period of at least 7 days. Participants received a single oral dose of saxagliptin, 5 mg/metformin, 1000 mg FDC, in the fasted state (Treatment E).", "interventionNames": ["Drug: Saxagliptin", "Drug: Saxagliptin/Metformin FDC", "Drug: Metformin"]}, {"label": "Arm 4: Treatments G,H/H,G", "type": "EXPERIMENTAL", "description": "Period 1: Participants received a single oral dose of saxagliptin , 5 mg/metformin, 1000 mg fixed-dose combination (FDC), in the fed state (Treatment G), followed by a washout period of at least 7 days. Participants received a single oral dose of saxagliptin, 5-mg and metformin extended-release (XR), 1000-mg tablets together in the fed state (Treatment H). Followed by a washout period of at least 4 days.\n\nPeriod 2: Participants received a single oral dose of saxagliptin, 5-mg and metformin XR, 1000-mg tablets together in the fed state (Treatment H), followed by a washout period of at least 7 days. Participants received a single oral dose of saxagliptin, 5 mg/metformin, 1000 mg FDC, in the fed state (Treatment G).", "interventionNames": ["Drug: Saxagliptin", "Drug: Saxagliptin/Metformin FDC", "Drug: Metformin"]}], "interventions": [{"type": "DRUG", "name": "Saxagliptin/metformin fixed-dose combination (FDC)", "description": "Tablet, oral, 5 mg/500 mg FDC, once on Day 1 only, 1 day", "armGroupLabels": ["Arm 1: Treatments A,B/B,A", "Arm 2: Treatments C,D/D,C"], "otherNames": ["Onglyza/Glucophage extended release (XR)"]}, {"type": "DRUG", "name": "Saxagliptin", "description": "Tablet, oral, 5 mg, once on Day 1 only, 1 day", "armGroupLabels": ["Arm 1: Treatments A,B/B,A", "Arm 2: Treatments C,D/D,C", "Arm 3: Treatments E, F/F,E", "Arm 4: Treatments G,H/H,G"], "otherNames": ["Onglyza"]}, {"type": "DRUG", "name": "Metformin extended-release (XR)", "description": "Tablet, oral, 500 mg, once on Day 1 only, 1 day", "armGroupLabels": ["Arm 1: Treatments A,B/B,A", "Arm 2: Treatments C,D/D,C"], "otherNames": ["Glifage XR"]}, {"type": "DRUG", "name": "Saxagliptin/Metformin FDC", "description": "Tablet, Oral, 5 mg/1000 mg FDC, once on Day 1 only, 1 day", "armGroupLabels": ["Arm 3: Treatments E, F/F,E", "Arm 4: Treatments G,H/H,G"], "otherNames": ["Onglyza/Glucophage XR"]}, {"type": "DRUG", "name": "Metformin", "description": "Tablet, oral, 1000 mg, once on Day 1 only, 1 day", "armGroupLabels": ["Arm 3: Treatments E, F/F,E", "Arm 4: Treatments G,H/H,G"], "otherNames": ["Glifage XR"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Maximum Observed Concentrations (Cmax) of Metformin, Saxagliptin, and 5-Hydroxy (5-OH) Saxagliptin as a Fixed-dose Combination (FDC) and as Individual Tablets", "timeFrame": "Days 1, 2, and 3 of Periods 1 and 2"}, {"measure": "AUC From Time 0 to Time of the Last Quantifiable Concentration (AUC[0-T])of Metformin, Saxagliptin, and 5-Hydroxy (5-OH) Saxagliptin as a Fixed-dose Combination (FDC) and as Individual Tablets", "description": "AUC=Area under the concentration-time curve", "timeFrame": "Days 1, 2, and 3 of Periods 1 and 2"}, {"measure": "AUC From Time 0 Extrapolated to Infinite Time (AUC[0-inf]) for Metformin, Saxagliptin, and 5-Hydroxy (5-OH) Saxagliptin as a Fixed-dose Combination (FDC) and as Individual Tablets", "description": "AUC=Area Under the Concentration-time Curve", "timeFrame": "Days 1, 2, and 3 of Periods 1 and 2"}], "secondaryOutcomes": [{"measure": "Number of Participants With Death as Outcome and Serious Adverse Events (SAEs)", "description": "SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization.", "timeFrame": "Continuously, from screening through Day 1 to within 30 days of drug discontinuation on Day 1"}]}, "eligibilityModule": {"eligibilityCriteria": "Key Inclusion Criteria:\n\n* Healthy men and women\n* women of childbearing potential who are using acceptable method of contraception\n* Women who are not pregnant or nursing\n* Body Mass Index (BMI) of 18 to 29.9 kg/m\\^2, inclusive. BMI=weight(kg)/height(m)\\^2.\n\nKey Exclusion Criteria:\n\n* Any significant acute or chronic medical illness.\n* History of gastrointestinal (GI) disease\n* Major surgery within 4 weeks of study drug administration\n* Any GI surgery that could impact study drug absorption\n* Donation of blood or plasma to a blood bank or in a clinical study (except a screening visit) within the 6 months of study drug administration.\n* Blood transfusion within 3 months of study drug administration for women and within 2 months for men\n* Inability to be venipunctured and/or tolerate venous access\n* Current smoker or recent (within 1 month) history of regular tobacco use\n* Recent (within 6 months of study drug administration) drug or alcohol abuse\n* Participation in a bioequivalence study within the last 6 months of study drug administration\n* Estimated creatinine clearance of \\<80 mL/min using Cockcroft-Gault formula\n* History of allergy to drug class or related compounds\n* History of allergy to metformin or other similar acting agents\n* History of any significant drug allergy", "healthyVolunteers": true, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "55 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Bristol-Myers Squibb", "affiliation": "Bristol-Myers Squibb", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Local Institution", "city": "Campinas", "state": "Sao Paulo", "zip": "13073", "country": "Brazil", "geoPoint": {"lat": -22.90556, "lon": -47.06083}}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Arm 1: Treatments A/B, B/A", "description": "Period 1: Participants received a single oral dose of saxagliptin, 5 mg/metformin, 500 mg fixed-dose combination (FDC) in the fasted state (Treatment A), followed by a washout period of at least 7 days. Then, participants received single oral doses of saxagliptin, 5-mg, and metformin extended-release (XR), 500-mg, tablets together in the fasted state (Treatment B). Followed by a washout period of at least 4 days.\n\nPeriod 2: Participants received single oral doses of saxagliptin, 5-mg and metformin XR, 500-mg tablets together in the fasted state (Treatment B), followed by a washout period of at least 7 days. Then, participants received a single oral dose of saxagliptin, 5 mg/metformin, 500 mg FDC, in the fasted state (Treatment A)."}, {"id": "FG001", "title": "Arm 2: Treatments C/D, D/C", "description": "Period 1: Participants received a single oral dose of saxagliptin, 5 mg/metformin, 500 mg fixed-dose combination (FDC), in the fed state (Treatment C), followed by a washout period of at least 7 days. Then, participants received a single oral dose of saxagliptin, 5-mg, and metformin extended-release (XR), 500-mg tablets together in the fed state (Treatment D). Followed by a washout period of at least 4 days.\n\nPeriod 2: Participants received a single oral dose of saxagliptin, 5-mg and metforminXR, 500-mg tablets together in the fed state (Treatment D), followed by a washout period of at least 7 days. Participants received a single oral dose of saxagliptin, 5 mg/metformin, 500 mg FDC, in the fed state (Treatment C)."}, {"id": "FG002", "title": "Arm 3:Treatments E/ F, F/E", "description": "Period 1: Participants received a single oral dose of saxagliptin, 5 mg/metformin, 1000 mg fixed-dose combination (FDC), in the fasted state (Treatment E), followed by a washout period of at least 7 days. Participants received single oral doses of saxagliptin, 5-mg and metformin extended-release (XR), 1000-mg tablets together in the fasted state (Treatment F). Followed by a washout period of at least 4 days.\n\nPeriod 2: Participants received single oral doses of saxagliptin, 5- mg and metformin XR, 1000-mg tablets together in the fasted state (Treatment F), followed by a washout period of at least 7 days. Participants received a single oral dose of saxagliptin, 5 mg/metformin, 1000 mg FDC, in the fasted state (Treatment E)."}, {"id": "FG003", "title": "Arm 4: Treatments G/ H, H/G", "description": "Period 1: Participants received a single oral dose of saxagliptin , 5 mg/metformin, 1000 mg fixed-dose combination (FDC), in the fed state (Treatment G), followed by a washout period of at least 7 days. Participants received a single oral dose of saxagliptin, 5-mg and metformin extended-release (XR), 1000-mg tablets together in the fed state (Treatment H). Followed by a washout period of at least 4 days.\n\nPeriod 2: Participants received a single oral dose of saxagliptin, 5-mg and metformin XR, 1000-mg tablets together in the fed state (Treatment H), followed by a washout period of at least 7 days. Participants received a single oral dose of saxagliptin, 5 mg/metformin, 1000 mg FDC, in the fed state (Treatment G)."}], "periods": [{"title": "Period 1", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "28"}, {"groupId": "FG001", "numSubjects": "28"}, {"groupId": "FG002", "numSubjects": "28"}, {"groupId": "FG003", "numSubjects": "28"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "26"}, {"groupId": "FG001", "numSubjects": "26"}, {"groupId": "FG002", "numSubjects": "25"}, {"groupId": "FG003", "numSubjects": "25"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "2"}, {"groupId": "FG002", "numSubjects": "3"}, {"groupId": "FG003", "numSubjects": "3"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "2"}, {"groupId": "FG003", "numSubjects": "3"}]}, {"type": "Positive test result for drugs of abuse", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}]}, {"type": "No longer met study criteria", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}]}, {"type": "Personal reasons", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "0"}]}]}, {"title": "Period 2", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "26"}, {"groupId": "FG001", "numSubjects": "26"}, {"groupId": "FG002", "numSubjects": "25"}, {"groupId": "FG003", "numSubjects": "25"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "25"}, {"groupId": "FG001", "numSubjects": "26"}, {"groupId": "FG002", "numSubjects": "24"}, {"groupId": "FG003", "numSubjects": "25"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "0"}]}], "dropWithdraws": [{"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}]}, {"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Arm 1: Treatments A/B, B/A", "description": "Period 1: Participants received a single oral dose of saxagliptin, 5 mg/metformin, 500 mg fixed-dose combination (FDC) in the fasted state (Treatment A), followed by a washout period of at least 7 days. Then, participants received single oral doses of saxagliptin, 5-mg, and metformin extended-release (XR), 500-mg, tablets together in the fasted state (Treatment B). Followed by a washout period of at least 4 days.\n\nPeriod 2: Participants received single oral doses of saxagliptin, 5-mg and metformin XR, 500-mg tablets together in the fasted state (Treatment B), followed by a washout period of at least 7 days. Then, participants received a single oral dose of saxagliptin, 5 mg/metformin, 500 mg FDC, in the fasted state (Treatment A)."}, {"id": "BG001", "title": "Arm 2: Treatments C/D, D/C", "description": "Period 1: Participants received a single oral dose of saxagliptin, 5 mg/metformin, 500 mg fixed-dose combination (FDC), in the fed state (Treatment C), followed by a washout period of at least 7 days. Then, participants received a single oral dose of saxagliptin, 5-mg, and metformin extended-release (XR), 500-mg tablets together in the fed state (Treatment D). Followed by a washout period of at least 4 days.\n\nPeriod 2: Participants received a single oral dose of saxagliptin, 5-mg and metforminXR, 500-mg tablets together in the fed state (Treatment D), followed by a washout period of at least 7 days. Participants received a single oral dose of saxagliptin, 5 mg/metformin, 500 mg FDC, in the fed state (Treatment C)."}, {"id": "BG002", "title": "Arm 3:Treatments E/ F, F/E", "description": "Period 1: Participants received a single oral dose of saxagliptin, 5 mg/metformin, 1000 mg fixed-dose combination (FDC), in the fasted state (Treatment E), followed by a washout period of at least 7 days. Participants received single oral doses of saxagliptin, 5-mg and metformin extended-release (XR), 1000-mg tablets together in the fasted state (Treatment F). Followed by a washout period of at least 4 days.\n\nPeriod 2: Participants received single oral doses of saxagliptin, 5- mg and metformin XR, 1000-mg tablets together in the fasted state (Treatment F), followed by a washout period of at least 7 days. Participants received a single oral dose of saxagliptin, 5 mg/metformin, 1000 mg FDC, in the fasted state (Treatment E)."}, {"id": "BG003", "title": "Arm 4: Treatments G/ H, H/G", "description": "Period 1: Participants received a single oral dose of saxagliptin , 5 mg/metformin, 1000 mg fixed-dose combination (FDC), in the fed state (Treatment G), followed by a washout period of at least 7 days. Participants received a single oral dose of saxagliptin, 5-mg and metformin extended-release (XR), 1000-mg tablets together in the fed state (Treatment H). Followed by a washout period of at least 4 days.\n\nPeriod 2: Participants received a single oral dose of saxagliptin, 5-mg and metformin XR, 1000-mg tablets together in the fed state (Treatment H), followed by a washout period of at least 7 days. Participants received a single oral dose of saxagliptin, 5 mg/metformin, 1000 mg FDC, in the fed state (Treatment G)."}, {"id": "BG004", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "28"}, {"groupId": "BG001", "value": "28"}, {"groupId": "BG002", "value": "28"}, {"groupId": "BG003", "value": "28"}, {"groupId": "BG004", "value": "112"}]}], "measures": [{"title": "Age, Customized", "paramType": "NUMBER", "unitOfMeasure": "Participants", "classes": [{"title": "<=18 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}]}]}, {"title": "Between 18 and 55 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "28"}, {"groupId": "BG001", "value": "28"}, {"groupId": "BG002", "value": "28"}, {"groupId": "BG003", "value": "28"}, {"groupId": "BG004", "value": "112"}]}]}, {"title": ">=55 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}]}]}]}, {"title": "Sex/Gender, Customized", "description": "The clinical study report (CSR) stated only that participants of both genders were enrolled. The CSR did not report the number of each gender enrolled.", "paramType": "NUMBER", "unitOfMeasure": "Participants", "classes": [{"title": "Both genders", "categories": [{"measurements": [{"groupId": "BG000", "value": "28"}, {"groupId": "BG001", "value": "28"}, {"groupId": "BG002", "value": "28"}, {"groupId": "BG003", "value": "28"}, {"groupId": "BG004", "value": "112"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Maximum Observed Concentrations (Cmax) of Metformin, Saxagliptin, and 5-Hydroxy (5-OH) Saxagliptin as a Fixed-dose Combination (FDC) and as Individual Tablets", "populationDescription": "Participants who received study medication and were evaluable", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "\u03bcg/mL", "timeFrame": "Days 1, 2, and 3 of Periods 1 and 2", "groups": [{"id": "OG000", "title": "Sax, 5 mg/Met 500 mg XR FDC vs Individual Tablets, Fasted", "description": "Arm 1: Treatments A, B/B, A. Period 1: Participants received a single oral dose of saxagliptin (sax), 5-mg/metformin (met), 500-mg extended-release (XR) fixed-dose combination (FDC) in the fasted state (Treatment A), followed by a washout period of at least 7 days. Then, participants received single oral doses of saxagliptin, 5-mg, and metformin XR, 500-mg tablets together in the fasted state (Treatment B). Followed by a washout period of at least 4 days.\n\nPeriod 2: Participants received single oral doses of saxagliptin, 5-mg and metformin XR, 500-mg tablets together in the fasted state (Treatment B), followed by a washout period of at least 7 days. Then, participants received a single oral dose of saxagliptin, 5 mg/metformin, 500-mg FDC, in the fasted state (Treatment A)."}, {"id": "OG001", "title": "Sax, 5 mg/Met 500 mg vs FDC to Individual Tablets, Fed", "description": "Arm 2: Treatment C, D/D, C. Period 1: Participants received a single oral dose of saxagliptin (sax) 5-mg/metformin (met) 500-mg, extended-release (XR) fixed-dose combination (FDC), in the fed state (Treatment C), followed by a washout period of at least 7 days. Then, participants received a single oral dose of saxagliptin, 5-mg, and metformin XR, 500-mg tablets together in the fed state (Treatment D). Followed by a washout period of at least 4 days.\n\nPeriod 2: Participants received a single oral dose of saxagliptin, 5-mg and metformin XR, 500-mg tablets together in the fed state (Treatment D), followed by a washout period of at least 7 days. Participants received a single oral dose of saxagliptin, 5-mg/metformin, 500-mg XR FDC, in the fed state (Treatment C)."}, {"id": "OG002", "title": "Sax, 5 mg/Met 1000 mg XR FDC to Individual Tablets, Fasted", "description": "Arm 3: Treatment E, F/F, G. Period 1: Participants received a single oral dose of saxagliptin (sax), 5-mg/metformin (met), 1000-mg extended-release (XR) fixed-dose combination (FDC), in the fasted state (Treatment E), followed by a washout period of at least 7 days. Participants received single oral doses of saxagliptin, 5-mg, and metformin XR, 1000-mg tablets, together in the fasted state (Treatment F). Followed by a washout period of at least 4 days.\n\nPeriod 2: Participants received single oral doses of saxagliptin, 5-mg and metformin XR, 1000-mg tablets together in the fasted state (Treatment F), followed by a washout period of at least 7 days. Participants received a single oral dose of saxagliptin, 5-mg/metformin, 1000-mg FDC, in the fasted state (Treatment E)."}, {"id": "OG003", "title": "Sax, 5 mg/Met 1000 mg XR FDC to Individual Tablets, Fed", "description": "Arm 4: Treatments G,H/H,G. Period 1: Participants received a single oral dose of saxagliptin (sax), 5-mg/metformin (met), 1000-mg extended-release (XR) fixed-dose combination (FDC), in the fed state (Treatment G), followed by a washout period of at least 7 days. Participants received a single oral dose of saxagliptin, 5-mg and metformin XR, 1000-mg tablets together in the fed state (Treatment H). Followed by a washout period of at least 4 days.\n\nPeriod 2: Participants received a single oral dose of saxagliptin, 5-mg and metformin XR, 1000-mg tablets together in the fed state (Treatment H), followed by a washout period of at least 7 days. Participants received a single oral dose of saxagliptin, 5-mg/metformin, 1000-mg FDC, in the fed state (Treatment G)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "25"}, {"groupId": "OG001", "value": "26"}, {"groupId": "OG002", "value": "24"}, {"groupId": "OG003", "value": "25"}]}], "classes": [{"title": "Metformin Cmax (individual tablet)", "categories": [{"measurements": [{"groupId": "OG000", "value": "713", "spread": "176", "lowerLimit": "87.618", "upperLimit": "103.446"}, {"groupId": "OG001", "value": "654", "spread": "118", "lowerLimit": "82.368", "upperLimit": "94.419"}, {"groupId": "OG002", "value": "1177", "spread": "399", "lowerLimit": "90.376", "upperLimit": "105.404"}, {"groupId": "OG003", "value": "1077", "spread": "139", "lowerLimit": "95.164", "upperLimit": "105.139"}]}]}, {"title": "Metformin Cmax (FDC)", "categories": [{"measurements": [{"groupId": "OG000", "value": "678", "spread": "167"}, {"groupId": "OG001", "value": "577", "spread": "95"}, {"groupId": "OG002", "value": "1139", "spread": "325"}, {"groupId": "OG003", "value": "1091", "spread": "214"}]}]}, {"title": "Saxagliptin Cmax (individual tablet)", "categories": [{"measurements": [{"groupId": "OG000", "value": "29274", "spread": "10209", "lowerLimit": "96.552", "upperLimit": "119.924"}, {"groupId": "OG001", "value": "28339", "spread": "7339", "lowerLimit": "92.263", "upperLimit": "104.451"}, {"groupId": "OG002", "value": "30914", "spread": "7965", "lowerLimit": "96.956", "upperLimit": "109.407"}, {"groupId": "OG003", "value": "31319", "spread": "6270", "lowerLimit": "89.055", "upperLimit": "98.470"}]}]}, {"title": "Saxagliptin Cmax (FDC)", "categories": [{"measurements": [{"groupId": "OG000", "value": "31372", "spread": "11367"}, {"groupId": "OG001", "value": "28140", "spread": "8311"}, {"groupId": "OG002", "value": "33549", "spread": "7813"}, {"groupId": "OG003", "value": "29545", "spread": "6006"}]}]}, {"title": "5-OH Saxagliptin Cmax (individual tablets)", "categories": [{"measurements": [{"groupId": "OG000", "value": "54709", "spread": "16816", "lowerLimit": "96.504", "upperLimit": "112.883"}, {"groupId": "OG001", "value": "52628", "spread": "12850", "lowerLimit": "91.470", "upperLimit": "98.714"}, {"groupId": "OG002", "value": "56444", "spread": "14731", "lowerLimit": "96.589", "upperLimit": "108.52"}, {"groupId": "OG003", "value": "55177", "spread": "13751", "lowerLimit": "95.572", "upperLimit": "103.144"}]}]}, {"title": "5-OH Saxagliptin Cmax (FDC)", "categories": [{"measurements": [{"groupId": "OG000", "value": "56413", "spread": "15775"}, {"groupId": "OG001", "value": "11316", "spread": "45404"}, {"groupId": "OG002", "value": "59878", "spread": "15959"}, {"groupId": "OG003", "value": "54521", "spread": "12319"}]}]}], "analyses": [{"groupIds": ["OG000"], "testedNonInferiority": true, "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "Metformin, Arm 1: The corresponding power and coefficient of variation between test and reference drugs are 98% and 17.24%, respectively", "statisticalMethod": "ANCOVA", "paramType": "Geometric mean ratio", "paramValue": "95.204", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "87.618", "ciUpperLimit": "103.446", "estimateComment": "Geometric mean ratio is calculated as B/A, where A=individual tablets (reference value) and B=FDC (test value)"}, {"groupIds": ["OG000"], "testedNonInferiority": true, "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "Saxagliptin, Arm 1: The corresponding power and coefficient of variation are 80% and 22.62%, respectively.", "statisticalMethod": "ANCOVA", "paramType": "Geometric mean ratio", "paramValue": "107.606", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "96.552", "ciUpperLimit": "119.924", "estimateComment": "Geometric mean ratio is calculated as B/A, where A=individual tablets (reference value) and B=FDC (test value)"}, {"groupIds": ["OG000"], "testedNonInferiority": true, "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "5-OH Saxagliptin, Arm 1: The corresponding power and the coefficient of variation are 99% and 16.26%, respectively.", "paramType": "Geometric mean ratio", "paramValue": "104.373", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "96.504", "ciUpperLimit": "112.883", "estimateComment": "Geometric mean ratio is calculated as B/A, where A=individual tablets (reference value) and B= FDC (test value)"}, {"groupIds": ["OG001"], "testedNonInferiority": true, "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "Metformin, Arm 2: The corresponding power and the variation coefficient are 81% and 14.42%,respectively.", "statisticalMethod": "ANCOVA", "paramType": "Geometric mean ratio", "paramValue": "88.188", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "82.368", "ciUpperLimit": "94.419", "estimateComment": "Geometric mean ratio is calculated as B/A, where A=individual tablets (reference value) and B=FDC (test value)"}, {"groupIds": ["OG001"], "testedNonInferiority": true, "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "Saxagliptin, Arm 2: The corresponding power and the variation coefficient are 99% and 13.09%, respectively.", "statisticalMethod": "ANCOVA", "paramType": "Geometric mean ratio", "paramValue": "98.168", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "92.263", "ciUpperLimit": "104.451", "estimateComment": "Geometric mean ratio is calculated as B/A, where A=individual tablets (reference value) and B=FDC (test value)"}, {"groupIds": ["OG001"], "testedNonInferiority": true, "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "5-OH saxagliptin, Arm 2: The corresponding power and the variation coefficient are 99% and 8.02%, respectively.", "statisticalMethod": "ANCOVA", "paramType": "Geometric mean ratio", "paramValue": "95.023", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "91.470", "ciUpperLimit": "98.714", "estimateComment": "Geometric mean ratio is calculated as B/A, where A=individual tablets (reference value) and B=FDC (test value)"}, {"groupIds": ["OG002"], "testedNonInferiority": true, "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "Metformin, Arm 3: The corresponding power and the variation coefficient are 99% and 15.55%, respectively.", "statisticalMethod": "ANCOVA", "paramType": "Geometric mean ratio", "paramValue": "97.601", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "15.55", "ciUpperLimit": "99", "estimateComment": "Geometric mean ratio is calculated as B/A, where A=individual tablets (reference value) and B=FDC (test value)"}, {"groupIds": ["OG002"], "testedNonInferiority": true, "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "Saxagliptin, Arm 3: The corresponding power and the variation coefficient are 84% and 15.65%, respectively.", "statisticalMethod": "ANCOVA", "paramType": "Geometric mean ratio", "paramValue": "110.656", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "102.416", "ciUpperLimit": "119.559", "estimateComment": "Geometric mean ratio is calculated as B/A, where A=individual tablets (reference value) and B=FDC (test value)"}, {"groupIds": ["OG002"], "testedNonInferiority": true, "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "OH-Saxagliptin, Arm 3: The corresponding power and the variation coefficient are 99% and 12.61%, respectively.", "statisticalMethod": "ANCOVA", "paramType": "Geometric mean ratio", "paramValue": "106.264", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "99.826", "ciUpperLimit": "113.117", "estimateComment": "Geometric mean ratio is calculated as B/A, where A=individual tablets (reference value) and B=FDC (test value)"}, {"groupIds": ["OG003"], "testedNonInferiority": true, "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "Metformin, Arm 4: The corresponding power and the variation coefficient are 99% and 10.30%, respectively.", "statisticalMethod": "ANCOVA", "paramType": "Geometric mean ratio", "paramValue": "100.028", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "95.164", "ciUpperLimit": "105.139", "estimateComment": "Geometric mean ratio is calculated as B/A, where A=individual tablets (reference value) and B=FDC (test value)"}, {"groupIds": ["OG003"], "testedNonInferiority": true, "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "Saxagliptin, Arm 4: The corresponding power and the variation coefficient are 99% and 10.38%, respectively.", "statisticalMethod": "ANCOVA", "statisticalComment": "Geometric mean ratio is calculated as B/A, where A=individual tablets (reference value) and B=FDC (test value)", "paramType": "Geometric mean ratio", "paramValue": "93.644", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "89.055", "ciUpperLimit": "98.470", "estimateComment": "Geometric mean ratio is calculated as B/A, where A=individual tablets (reference value) and B=FDC (test value)"}]}, {"type": "PRIMARY", "title": "AUC From Time 0 to Time of the Last Quantifiable Concentration (AUC[0-T])of Metformin, Saxagliptin, and 5-Hydroxy (5-OH) Saxagliptin as a Fixed-dose Combination (FDC) and as Individual Tablets", "description": "AUC=Area under the concentration-time curve", "populationDescription": "Participants who received study medication and were evaluable", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "pg*h/mL", "timeFrame": "Days 1, 2, and 3 of Periods 1 and 2", "groups": [{"id": "OG000", "title": "Sax, 5 mg/Met, 500 mg: Sax, 5 mg/Met, 500 mg FDC Fasting", "description": "Arm 1: Treatments A, B/B, A. Period 1: Participants received a single oral dose of saxagliptin (sax), 5-mg/metformin (met), 500-mg extended-release (XR) fixed-dose combination (FDC) in the fasted state (Treatment A), followed by a washout period of at least 7 days. Then, participants received single oral doses of saxagliptin, 5-mg, and metformin XR, 500-mg tablets together in the fasted state (Treatment B). Followed by a washout period of at least 4 days.\n\nPeriod 2: Participants received single oral doses of saxagliptin, 5-mg and metformin XR, 500-mg tablets together in the fasted state (Treatment B), followed by a washout period of at least 7 days. Then, participants received a single oral dose of saxagliptin, 5 mg/metformin, 500-mg FDC, in the fasted state (Treatment A)."}, {"id": "OG001", "title": "Sax, 5 mg/Met, 500 mg: Sax, 5 mg/Met 500 mg FDC Fed", "description": "Arm 2: Treatment C, D/D, C. Period 1: Participants received a single oral dose of saxagliptin (sax) 5-mg/metformin (met) 500-mg, extended-release (XR) fixed-dose combination (FDC), in the fed state (Treatment C), followed by a washout period of at least 7 days. Then, participants received a single oral dose of saxagliptin, 5-mg, and metformin XR, 500-mg tablets together in the fed state (Treatment D). Followed by a washout period of at least 4 days.\n\nPeriod 2: Participants received a single oral dose of saxagliptin, 5-mg and metformin XR, 500-mg tablets together in the fed state (Treatment D), followed by a washout period of at least 7 days. Participants received a single oral dose of saxagliptin, 5-mg/metformin, 500-mg XR FDC, in the fed state (Treatment C)."}, {"id": "OG002", "title": "Sax, 5 mg/Met XR, 1000 mg: Sax, 5 mg/Met, 1000 mg FDC Fasting", "description": "Arm 3: Treatment E, F/F, G. Period 1: Participants received a single oral dose of saxagliptin (sax), 5-mg/metformin (met), 1000-mg extended-release (XR) fixed-dose combination (FDC), in the fasted state (Treatment E), followed by a washout period of at least 7 days. Participants received single oral doses of saxagliptin, 5-mg, and metformin XR, 1000-mg tablets, together in the fasted state (Treatment F). Followed by a washout period of at least 4 days.\n\nPeriod 2: Participants received single oral doses of saxagliptin, 5-mg and metformin XR, 1000-mg tablets together in the fasted state (Treatment F), followed by a washout period of at least 7 days. Participants received a single oral dose of saxagliptin, 5-mg/metformin, 1000-mg FDC, in the fasted state (Treatment E)."}, {"id": "OG003", "title": "Sax, 5 mg/Met XR, 1000 mg: Sax, 5 mg/Met, 1000 mg FDC Fed", "description": "Arm 4: Treatments G,H/H,G. Period 1: Participants received a single oral dose of saxagliptin (sax), 5-mg/metformin (met), 1000-mg extended-release (XR) fixed-dose combination (FDC), in the fed state (Treatment G), followed by a washout period of at least 7 days. Participants received a single oral dose of saxagliptin, 5-mg and metformin XR, 1000-mg tablets together in the fed state (Treatment H). Followed by a washout period of at least 4 days.\n\nPeriod 2: Participants received a single oral dose of saxagliptin, 5-mg and metformin XR, 1000-mg tablets together in the fed state (Treatment H), followed by a washout period of at least 7 days. Participants received a single oral dose of saxagliptin, 5-mg/metformin, 1000-mg FDC, in the fed state (Treatment G)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "25"}, {"groupId": "OG001", "value": "26"}, {"groupId": "OG002", "value": "24"}, {"groupId": "OG003", "value": "25"}]}], "classes": [{"title": "Metformin AUC(0-T) (individual tablets)", "categories": [{"measurements": [{"groupId": "OG000", "value": "5816", "spread": "1859", "lowerLimit": "82.596", "upperLimit": "101.380"}, {"groupId": "OG001", "value": "5071", "spread": "821", "lowerLimit": "85.560", "upperLimit": "98.035"}, {"groupId": "OG002", "value": "8174", "spread": "2394", "lowerLimit": "96.956", "upperLimit": "109.407"}, {"groupId": "OG003", "value": "9628", "spread": "3270", "lowerLimit": "85.502", "upperLimit": "101.053"}]}]}, {"title": "Metformin AUC(0-T) (FDC)", "categories": [{"measurements": [{"groupId": "OG000", "value": "5386", "spread": "1896"}, {"groupId": "OG001", "value": "4701", "spread": "1028"}, {"groupId": "OG002", "value": "8500", "spread": "2713"}, {"groupId": "OG003", "value": "8936", "spread": "2696"}]}]}, {"title": "Saxagliptin AUC(0-T) (individual tablets)", "categories": [{"measurements": [{"groupId": "OG000", "value": "106070", "spread": "26733"}, {"groupId": "OG001", "value": "110285", "spread": "22139"}, {"groupId": "OG002", "value": "102913", "spread": "22067"}, {"groupId": "OG003", "value": "124536", "spread": "24794", "lowerLimit": "98.494", "upperLimit": "104.147"}]}]}, {"title": "Saxagliptin AUC(0-T) (FDC)", "categories": [{"measurements": [{"groupId": "OG000", "value": "103865", "spread": "31088"}, {"groupId": "OG001", "value": "109345", "spread": "23947"}, {"groupId": "OG002", "value": "99215", "spread": "20146"}, {"groupId": "OG003", "value": "127232", "spread": "28709"}]}]}, {"title": "5-OH Saxagliptin AUC(0-T) (individual tablets)", "categories": [{"measurements": [{"groupId": "OG000", "value": "320743", "spread": "68176"}, {"groupId": "OG001", "value": "305354", "spread": "53254"}, {"groupId": "OG002", "value": "324163", "spread": "59358"}, {"groupId": "OG003", "value": "9628", "spread": "3270"}]}]}, {"title": "5-OH Saxagliptin AUC(0-T) (FDC)", "categories": [{"measurements": [{"groupId": "OG000", "value": "331332", "spread": "67491"}, {"groupId": "OG001", "value": "292515", "spread": "45404"}, {"groupId": "OG002", "value": "323039", "spread": "56031", "lowerLimit": "96.512", "upperLimit": "103.648"}, {"groupId": "OG003", "value": "8936", "spread": "2696", "lowerLimit": "97.367", "upperLimit": "102.932"}]}]}], "analyses": [{"groupIds": ["OG000"], "testedNonInferiority": true, "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "Metformin, Arm 1: The corresponding power and coefficient of variation are 98% and 17.24%, respectively.", "statisticalMethod": "ANCOVA", "paramType": "Geometric mean ratio", "paramValue": "91.508", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "82.596", "ciUpperLimit": "101.380", "estimateComment": "Geometric mean ratio is calculated as B/A, where A=individual tablets (reference value) and B=FDC (test value)"}, {"groupIds": ["OG000"], "testedNonInferiority": true, "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "Saxagliptin, Arm 1: The corresponding power and the coefficient of variation are 99% and 07.66%, respectively.", "statisticalMethod": "ANCOVA", "paramType": "Geometric mean ratio", "paramValue": "97.437", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "93.889", "ciUpperLimit": "101.119", "estimateComment": "Geometric mean ratio is calculated as B/A, where A=individual tablets (reference value) and B=FDC (test value)"}, {"groupIds": ["OG000"], "testedNonInferiority": true, "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "5-OH Saxagliptin, Arm 1: The corresponding power and the coefficient of variation are 99% and 07.43%, respectively.", "statisticalMethod": "ANCOVA", "paramType": "Geometric mean ratio", "paramValue": "96.770", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "93.350", "ciUpperLimit": "100.316", "estimateComment": "Geometric mean ratio is calculated as B/A, where A=individual tablets (reference value) and B=FDC (test value)"}, {"groupIds": ["OG001"], "testedNonInferiority": true, "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "Metformin, Arm 2: The corresponding power and the variation coefficient are 96% and 14.37%, respectively.", "statisticalMethod": "ANCOVA", "paramType": "Geometric mean ratio", "paramValue": "91.585", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "85.56", "ciUpperLimit": "98.035", "estimateComment": "Geometric mean ratio is calculated as B/A, where A=individual tablets (reference value) and B=FDC (test value)"}, {"groupIds": ["OG001"], "testedNonInferiority": true, "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "Saxagliptin, Arm 2: The corresponding power and the variation coefficient are 96.028% and 101.095%, respectively.", "statisticalMethod": "ANCOVA", "paramType": "Geometric mean ratio", "paramValue": "98.529", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "96.028", "ciUpperLimit": "101.095", "estimateComment": "Geometric mean ratio is calculated as B/A, where A=individual tablets (reference value) and B=FDC (test value)"}, {"groupIds": ["OG001"], "testedNonInferiority": true, "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "5-OH Saxagliptin, Arm 2: The corresponding power and the variation coefficient are 99% and 6.55%, respectively", "statisticalMethod": "ANCOVA", "paramType": "Geometric mean ratio", "paramValue": "96.239", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "93.286", "ciUpperLimit": "99.286", "estimateComment": "Geometric mean ratio is calculated as B/A, where A=individual tablets (reference value) and B=FDC (test value)"}, {"groupIds": ["OG002"], "testedNonInferiority": true, "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "Metformin, Arm 3: The corresponding power and the variation coefficient are 99% and 12.19%, respectively.", "statisticalMethod": "ANCOVA", "paramType": "Geometric mean ratio", "paramValue": "102.994", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "96.956", "ciUpperLimit": "109.407", "estimateComment": "Geometric mean ratio is calculated as B/A, where A=individual tablets (reference value) and B=FDC (test value)"}, {"groupIds": ["OG002"], "testedNonInferiority": true, "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "Saxagliptin, Arm 3: The corresponding power and the variation coefficient are 99% and 7.07%, respectively.", "statisticalMethod": "ANCOVA", "paramType": "Geometric mean ratio", "paramValue": "97.135", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "93.778", "ciUpperLimit": "100.613", "estimateComment": "Geometric mean ratio is calculated as B/A, where A=individual tablets (reference value) and B=FDC (test value)"}, {"groupIds": ["OG002"], "testedNonInferiority": true, "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "5-OH Saxagliptin, Arm 3: The corresponding power and the variation coefficient are 99% and 7.18%, respectively.", "statisticalMethod": "ANCOVA", "paramType": "Geometric mean ratio", "paramValue": "100.01", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "96.512", "ciUpperLimit": "103.648", "estimateComment": "Geometric mean ratio is calculated as B/A, where A=individual tablets (reference value) and B=FDC (test value)"}, {"groupIds": ["OG003"], "testedNonInferiority": true, "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "Metformin, Arm 1:The corresponding power and the variation coefficient are 93% and 17.35%, respectively.", "statisticalMethod": "ANCOVA", "paramType": "Geometric mean ratio", "paramValue": "92.953", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "85.502", "ciUpperLimit": "101.053", "estimateComment": "Geometric mean ratio is calculated as B/A, where A=individual tablets (reference value) and B=FDC (test value)"}, {"groupIds": ["OG003"], "testedNonInferiority": true, "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "Saxagliptin, Arm 4: The corresponding power and the variation coefficient are 99% and 5.75%, respectively.", "statisticalMethod": "ANCOVA", "paramType": "Geometric mean ratio", "paramValue": "101.281", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "98.494", "ciUpperLimit": "104.147", "estimateComment": "Geometric mean ratio is calculated as B/A, where A=individual tablets (reference value) and B=FDC (test value)"}, {"groupIds": ["OG003"], "testedNonInferiority": true, "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "5-OH Saxagliptin, Arm 4: The corresponding power and the variation coefficient are 99% and 5.73%, respectively.", "statisticalMethod": "ANCOVA", "paramType": "Geometric mean ratio", "paramValue": "100.111", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "97.367", "ciUpperLimit": "102.932", "estimateComment": "Geometric mean ratio is calculated as B/A, where A=individual tablets (reference value) and B=FDC (test value)"}]}, {"type": "SECONDARY", "title": "Number of Participants With Death as Outcome and Serious Adverse Events (SAEs)", "description": "SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization.", "populationDescription": "All enrolled participants who receive study medication", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "Continuously, from screening through Day 1 to within 30 days of drug discontinuation on Day 1", "groups": [{"id": "OG000", "title": "Arm 1: Treatments A,B/B,A", "description": "Period 1: Participants received a single oral dose of saxagliptin, 5 mg/metformin, 500 mg fixed-dose combination (FDC) in the fasted state (Treatment A), followed by a washout period of at least 7 days. Then, participants received single oral doses of saxagliptin, 5-mg, and metformin extended-release (XR), 500-mg, tablets together in the fasted state (Treatment B). Followed by a washout period of at least 4 days.\n\nPeriod 2: Participants received single oral doses of saxagliptin, 5-mg and metformin XR, 500-mg tablets together in the fasted state (Treatment B), followed by a washout period of at least 7 days. Then, participants received a single oral dose of saxagliptin, 5 mg/metformin, 500 mg FDC, in the fasted state (Treatment A)."}, {"id": "OG001", "title": "Arm 2: Treatments C,D/D,C", "description": "Period 1: Participants received a single oral dose of saxagliptin, 5 mg/metformin, 500 mg fixed-dose combination (FDC), in the fed state (Treatment C), followed by a washout period of at least 7 days. Then, participants received a single oral dose of saxagliptin, 5-mg, and metformin extended-release (XR), 500-mg tablets together in the fed state (Treatment D). Followed by a washout period of at least 4 days.\n\nPeriod 2: Participants received a single oral dose of saxagliptin, 5-mg and metforminXR, 500-mg tablets together in the fed state (Treatment D), followed by a washout period of at least 7 days. Participants received a single oral dose of saxagliptin, 5 mg/metformin, 500 mg FDC, in the fed state (Treatment C)."}, {"id": "OG002", "title": "Arm 3: Treatments E,F/ F,E", "description": "Period 1: Participants received a single oral dose of saxagliptin, 5 mg/metformin, 1000 mg fixed-dose combination (FDC), in the fasted state (Treatment E), followed by a washout period of at least 7 days. Participants received single oral doses of saxagliptin, 5-mg and metformin extended-release (XR), 1000-mg tablets together in the fasted state (Treatment F). Followed by a washout period of at least 4 days.\n\nPeriod 2: Participants received single oral doses of saxagliptin, 5- mg and metformin XR, 1000-mg tablets together in the fasted state (Treatment F), followed by a washout period of at least 7 days. Participants received a single oral dose of saxagliptin, 5 mg/metformin, 1000 mg FDC, in the fasted state (Treatment E)."}, {"id": "OG003", "title": "Arm 4: Treatments G,H/H,G", "description": "Period 1: Participants received a single oral dose of saxagliptin, 5 mg/metformin, 1000 mg fixed-dose combination (FDC), in the fed state (Treatment G), followed by a washout period of at least 7 days. Participants received a single oral dose of saxagliptin, 5-mg and metformin extended-release (XR), 1000-mg tablets together in the fed state (Treatment H). Followed by a washout period of at least 4 days.\n\nPeriod 2: Participants received a single oral dose of saxagliptin, 5-mg and metformin XR, 1000-mg tablets together in the fed state (Treatment H), followed by a washout period of at least 7 days. Participants received a single oral dose of saxagliptin, 5 mg/metformin, 1000 mg FDC, in the fed state (Treatment G)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "28"}, {"groupId": "OG001", "value": "28"}, {"groupId": "OG002", "value": "28"}, {"groupId": "OG003", "value": "28"}]}], "classes": [{"title": "Deaths", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}]}]}, {"title": "SAEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}]}]}]}, {"type": "PRIMARY", "title": "AUC From Time 0 Extrapolated to Infinite Time (AUC[0-inf]) for Metformin, Saxagliptin, and 5-Hydroxy (5-OH) Saxagliptin as a Fixed-dose Combination (FDC) and as Individual Tablets", "description": "AUC=Area Under the Concentration-time Curve", "populationDescription": "Participants who received study medication and were evaluable", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ng*h/mL", "timeFrame": "Days 1, 2, and 3 of Periods 1 and 2", "groups": [{"id": "OG000", "title": "Sax, 5 mg/Met 500 mg XR FDC to Individual Tablets, Fasted", "description": "Arm 1: Treatments A, B/B, A. Period 1: Participants received a single oral dose of saxagliptin (sax), 5-mg/metformin (met), 500-mg extended-release (XR) fixed-dose combination (FDC) in the fasted state (Treatment A), followed by a washout period of at least 7 days. Then, participants received single oral doses of saxagliptin, 5-mg, and metformin XR, 500-mg tablets together in the fasted state (Treatment B). Followed by a washout period of at least 4 days.\n\nPeriod 2: Participants received single oral doses of saxagliptin, 5-mg and metformin XR, 500-mg tablets together in the fasted state (Treatment B), followed by a washout period of at least 7 days. Then, participants received a single oral dose of saxagliptin, 5 mg/metformin, 500-mg FDC, in the fasted state (Treatment A)."}, {"id": "OG001", "title": "Sax, 5 mg/Met 500 mg XR FDC to Individual Tablets, Fed", "description": "Arm 2: Treatment C, D/D, C. Period 1: Participants received a single oral dose of saxagliptin (sax) 5-mg/metformin (met) 500-mg, extended-release (XR) fixed-dose combination (FDC), in the fed state (Treatment C), followed by a washout period of at least 7 days. Then, participants received a single oral dose of saxagliptin, 5-mg, and metformin XR, 500-mg tablets together in the fed state (Treatment D). Followed by a washout period of at least 4 days.\n\nPeriod 2: Participants received a single oral dose of saxagliptin, 5-mg and metformin XR, 500-mg tablets together in the fed state (Treatment D), followed by a washout period of at least 7 days. Participants received a single oral dose of saxagliptin, 5-mg/metformin, 500-mg XR FDC, in the fed state (Treatment C)."}, {"id": "OG002", "title": "Sax, 5 mg/Met 1000 mg XR FDC to Individual Tablets, Fasted", "description": "Arm 3: Treatment E, F/F, G. Period 1: Participants received a single oral dose of saxagliptin (sax), 5-mg/metformin (met), 1000-mg extended-release (XR) fixed-dose combination (FDC), in the fasted state (Treatment E), followed by a washout period of at least 7 days. Participants received single oral doses of saxagliptin, 5-mg, and metformin XR, 1000-mg tablets, together in the fasted state (Treatment F). Followed by a washout period of at least 4 days.\n\nPeriod 2: Participants received single oral doses of saxagliptin, 5-mg and metformin XR, 1000-mg tablets together in the fasted state (Treatment F), followed by a washout period of at least 7 days. Participants received a single oral dose of saxagliptin, 5-mg/metformin, 1000-mg FDC, in the fasted state (Treatment E)."}, {"id": "OG003", "title": "Sax, 5 mg/Met 1000 mg XR FDC to Individual Tablets, Fed", "description": "Arm 4: Treatments G,H/H,G. Period 1: Participants received a single oral dose of saxagliptin (sax), 5-mg/metformin (met), 1000-mg extended-release (XR) fixed-dose combination (FDC), in the fed state (Treatment G), followed by a washout period of at least 7 days. Participants received a single oral dose of saxagliptin, 5-mg and metformin XR, 1000-mg tablets together in the fed state (Treatment H). Followed by a washout period of at least 4 days.\n\nPeriod 2: Participants received a single oral dose of saxagliptin, 5-mg and metformin XR, 1000-mg tablets together in the fed state (Treatment H), followed by a washout period of at least 7 days. Participants received a single oral dose of saxagliptin, 5-mg/metformin, 1000-mg FDC, in the fed state (Treatment G)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "25"}, {"groupId": "OG001", "value": "26"}, {"groupId": "OG002", "value": "24"}, {"groupId": "OG003", "value": "25"}]}], "classes": [{"title": "Metformin AUC (0-inf) (individual tablets)", "categories": [{"measurements": [{"groupId": "OG000", "value": "5877", "spread": "1858"}, {"groupId": "OG001", "value": "5127", "spread": "816"}, {"groupId": "OG002", "value": "8338", "spread": "2414"}, {"groupId": "OG003", "value": "9731", "spread": "3277"}]}]}, {"title": "Metformin AUC (0-inf) (FDC)", "categories": [{"measurements": [{"groupId": "OG000", "value": "5443", "spread": "1905", "lowerLimit": "82.697", "upperLimit": "101.226"}, {"groupId": "OG001", "value": "4754", "spread": "1037", "lowerLimit": "85.573", "upperLimit": "97.939"}, {"groupId": "OG002", "value": "8618", "spread": "2726", "lowerLimit": "96.589", "upperLimit": "108.525"}, {"groupId": "OG003", "value": "9054", "spread": "2684", "lowerLimit": "85.835", "upperLimit": "101.238"}]}]}, {"title": "Saxagliptin AUC (0-inf) (individual tablets)", "categories": [{"measurements": [{"groupId": "OG000", "value": "107425", "spread": "26828", "lowerLimit": "93.955", "upperLimit": "101.132"}, {"groupId": "OG001", "value": "111677", "spread": "22315", "lowerLimit": "96.044", "upperLimit": "101.090"}, {"groupId": "OG002", "value": "104293", "spread": "22149", "lowerLimit": "93.832", "upperLimit": "100.662"}, {"groupId": "OG003", "value": "125820", "spread": "24856", "lowerLimit": "98.574", "upperLimit": "104.196"}]}]}, {"title": "Saxagliptin AUC (0-inf) (FDC)", "categories": [{"measurements": [{"groupId": "OG000", "value": "105248", "spread": "31314"}, {"groupId": "OG001", "value": "110705", "spread": "24091"}, {"groupId": "OG002", "value": "100620", "spread": "20264"}, {"groupId": "OG003", "value": "128602", "spread": "28729"}]}]}, {"title": "5-OH Saxagliptin AUC (0-inf) (individual tablets)", "categories": [{"measurements": [{"groupId": "OG000", "value": "337345", "spread": "67941", "lowerLimit": "93.393", "upperLimit": "100.247"}, {"groupId": "OG001", "value": "310983", "spread": "53447", "lowerLimit": "93.319", "upperLimit": "99.290"}, {"groupId": "OG002", "value": "330247", "spread": "59863", "lowerLimit": "96.560", "upperLimit": "103.594"}, {"groupId": "OG003", "value": "332495", "spread": "62192", "lowerLimit": "97.324", "upperLimit": "102.864"}]}]}, {"title": "5-OH Saxagliptin AUC (0-inf) (FDC)", "categories": [{"measurements": [{"groupId": "OG000", "value": "326501", "spread": "68475"}, {"groupId": "OG001", "value": "298037", "spread": "45636"}, {"groupId": "OG002", "value": "329085", "spread": "56298"}, {"groupId": "OG003", "value": "332869", "spread": "59469"}]}]}], "analyses": [{"groupIds": ["OG000"], "testedNonInferiority": true, "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "For AUC(0-inf) metformin, Arm 1, the corresponding power and coefficient of variation are 80% and 21.06%, respectively.", "statisticalMethod": "ANCOVA", "paramType": "Geometric mean ratio", "paramValue": "91.494", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "82.697", "ciUpperLimit": "101.226", "estimateComment": "Geometric mean ratio is calculated as B/A, where A=individual tablets (reference value) and B=FDC (test value)."}, {"groupIds": ["OG000"], "testedNonInferiority": true, "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "Saxagliptin, Arm 1: The corresponding power and the coefficient of variation are 99% and 07.60%, respectively.", "statisticalMethod": "ANCOVA", "paramType": "Geometric mean ratio", "paramValue": "97.477", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "93.955", "ciUpperLimit": "101.132", "estimateComment": "Geometric mean ratio is calculated as B/A, where A=individual tablets (reference value) and B=FDC (test value)"}, {"groupIds": ["OG000"], "testedNonInferiority": true, "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "5-OH Saxagliptin, Arm 1. The corresponding power and the coefficient of variation are 99% and 07.31%, respectively.", "statisticalMethod": "ANCOVA", "paramType": "Geometric mean ratio", "paramValue": "96.760", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "93.393", "ciUpperLimit": "100.247", "estimateComment": "Geometric mean ratio is calculated as B/A, where A=individual tablets (reference value) and B=FDC (test value)."}, {"groupIds": ["OG001"], "testedNonInferiority": true, "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "Metformin, Arm 2: The corresponding power and the variation coefficient are 96% and 14.25%, respectively.", "statisticalMethod": "ANCOVA", "paramType": "Geometric mean ratio", "paramValue": "91.548", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "85.573", "ciUpperLimit": "97.939", "estimateComment": "Geometric mean ratio is calculated as B/A, where A=individual tablets (reference value) and B=FDC (test value)"}, {"groupIds": ["OG001"], "testedNonInferiority": true, "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "Saxagliptin, Arm 2: The corresponding power and the variation coefficient are 99% and 5.38%,respectively.", "statisticalMethod": "ANCOVA", "paramType": "Geometric mean ratio", "paramValue": "98.535", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "96.044", "ciUpperLimit": "101.090", "estimateComment": "Geometric mean ratio is calculated as B/A, where A=individual tablets (reference value) and B=FDC (test value)"}, {"groupIds": ["OG001"], "testedNonInferiority": true, "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "5-OH Saxagliptin, Arm 2: The corresponding power and the variation coefficient are 99% and 6.52%, respectively.", "statisticalMethod": "ANCOVA", "paramType": "Geometric mean ratio", "paramValue": "96.258", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "93.319", "ciUpperLimit": "99.290", "estimateComment": "Geometric mean ratio is calculated as B/A, where A=individual tablets (reference value) and B=FDC (test value)"}, {"groupIds": ["OG002"], "testedNonInferiority": true, "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "Metformin, Arm 3: The corresponding power and the variation coefficient are 99% and 11.75%, respectively.", "statisticalMethod": "ANCOVA", "paramType": "Geometric mean ratio", "paramValue": "102.383", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "96.589", "ciUpperLimit": "108.525", "estimateComment": "Geometric mean ratio is calculated as B/A, where A=individual tablets (reference value) and B=FDC (test value)"}, {"groupIds": ["OG002"], "testedNonInferiority": true, "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "Saxagliptin, Arm 5: The corresponding power and the variation coefficient are 99% and 7.07%, respectively.", "statisticalMethod": "ANCOVA", "paramType": "Geometric mean ratio", "paramValue": "97.187", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "93.832", "ciUpperLimit": "100.662", "estimateComment": "Geometric mean ratio is calculated as B/A, where A=individual tablets (reference value) and B=FDC (test value)"}, {"groupIds": ["OG002"], "testedNonInferiority": true, "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "5-OH Sarexagliptin, Arm 3: The corresponding power and the variation coefficient are 99% and 7.08%, respectively.", "statisticalMethod": "ANCOVA", "paramType": "Geometric mean ratio", "paramValue": "100.015", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "96.560", "ciUpperLimit": "103.594", "estimateComment": "Geometric mean ratio is calculated as B/A, where A=individual tablets (reference value) and B=FDC (test value)"}, {"groupIds": ["OG002", "OG003"], "testedNonInferiority": true, "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "Metformin, Arm 4: The corresponding power and the variation coefficient are 94% and 17.13%, respectively.", "statisticalMethod": "ANCOVA", "paramType": "Geometric mean ratio", "paramValue": "93.219", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "85.835", "ciUpperLimit": "101.238"}, {"groupIds": ["OG003"], "testedNonInferiority": true, "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "Saxagliptin, Arm 4: The corresponding power and the variation coefficient are 99% and 5.72%, respectively.", "statisticalMethod": "ANCOVA", "paramType": "Geometric mean ratio", "paramValue": "101.346", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "98.574", "ciUpperLimit": "104.196", "estimateComment": "Geometric mean ratio is calculated as B/A, where A=individual tablets (reference value) and B=FDC (test value)"}, {"groupIds": ["OG003"], "testedNonInferiority": true, "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "5-OH Saxagliptin, Arm 4: The corresponding power and the variation coefficient are 99% and 5.71%, respectively.", "statisticalMethod": "ANCOVA", "paramType": "Geometric mean ratio", "paramValue": "100.056", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "97.324", "ciUpperLimit": "102.864", "estimateComment": "Geometric mean ratio is calculated as B/A, where A=individual tablets (reference value) and B=FDC (test value)"}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "From screening through Day 1 to within 30 days of drug discontinuation on Day 1", "eventGroups": [{"id": "EG000", "title": "Saxagliptin, 5 mg/Metformin XR, 1000 mg Fasting", "description": "XR=extended release", "seriousNumAffected": 0, "seriousNumAtRisk": 28, "otherNumAffected": 7, "otherNumAtRisk": 28}, {"id": "EG001", "title": "Saxagliptin, 5 mg/Metformin XR, 1000 mg Fed", "description": "XR=extended release", "seriousNumAffected": 0, "seriousNumAtRisk": 28, "otherNumAffected": 13, "otherNumAtRisk": 26}, {"id": "EG002", "title": "Saxagliptin, 5 mg/Metformin XR, 500 mg Fasting", "description": "XR=extended release", "seriousNumAffected": 0, "seriousNumAtRisk": 28, "otherNumAffected": 10, "otherNumAtRisk": 27}, {"id": "EG003", "title": "Saxagliptin, 5 mg/Metformin XR, 500 mg Fed", "description": "XR=extended release", "seriousNumAffected": 0, "seriousNumAtRisk": 28, "otherNumAffected": 6, "otherNumAtRisk": 26}, {"id": "EG004", "title": "Saxagliptin, 5 mg/Metformin, 1000 mg FDC Fasting", "description": "FDC=fixed-dose combination", "seriousNumAffected": 0, "seriousNumAtRisk": 28, "otherNumAffected": 8, "otherNumAtRisk": 25}, {"id": "EG005", "title": "Saxagliptin, 5 mg/Metformin, 1000 mg FDC Fed", "description": "FDC=fixed-dose combination", "seriousNumAffected": 0, "seriousNumAtRisk": 28, "otherNumAffected": 4, "otherNumAtRisk": 27}, {"id": "EG006", "title": "Saxagliptin, 5 mg/Metformin, 500 mg FDC Fasting", "description": "FDC=fixed-dose combination", "seriousNumAffected": 0, "seriousNumAtRisk": 28, "otherNumAffected": 8, "otherNumAtRisk": 28}, {"id": "EG007", "title": "Saxagliptin, 5 mg/Metformin, 500 mg FDC Fed", "description": "FDC=fixed-dose combination", "seriousNumAffected": 0, "seriousNumAtRisk": 28, "otherNumAffected": 14, "otherNumAtRisk": 28}], "otherEvents": [{"term": "Abdominal pain upper", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 28}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 26}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 27}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 26}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 25}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 27}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 28}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 28}]}, {"term": "Anaemia", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 28}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 26}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 27}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 26}, {"groupId": "EG004", "numAffected": 3, "numAtRisk": 25}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 27}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 28}, {"groupId": "EG007", "numAffected": 1, "numAtRisk": 28}]}, {"term": "White blood cell disorder", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 28}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 26}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 27}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 26}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 25}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 27}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 28}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 28}]}, {"term": "Dysgeusia", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 28}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 26}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 27}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 26}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 25}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 27}, {"groupId": "EG006", "numAffected": 2, "numAtRisk": 28}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 28}]}, {"term": "Alanine aminotransferase abnormal", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 28}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 26}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 27}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 26}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 25}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 27}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 28}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 28}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 28}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 26}, {"groupId": "EG002", "numAffected": 10, "numAtRisk": 27}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 26}, {"groupId": "EG004", "numAffected": 4, "numAtRisk": 25}, {"groupId": "EG005", "numAffected": 2, "numAtRisk": 27}, {"groupId": "EG006", "numAffected": 7, "numAtRisk": 28}, {"groupId": "EG007", "numAffected": 4, "numAtRisk": 28}]}, {"term": "Aptyalism", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 28}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 26}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 27}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 26}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 25}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 27}, {"groupId": "EG006", "numAffected": 1, "numAtRisk": 28}, {"groupId": "EG007", "numAffected": 2, "numAtRisk": 28}]}, {"term": "Hypertension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 28}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 26}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 27}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 26}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 25}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 27}, {"groupId": "EG006", "numAffected": 2, "numAtRisk": 28}, {"groupId": "EG007", "numAffected": 1, "numAtRisk": 28}]}, {"term": "Blood creatinine abnormal", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 28}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 26}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 27}, {"groupId": "EG003", "numAffected": 2, "numAtRisk": 26}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 25}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 27}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 28}, {"groupId": "EG007", "numAffected": 6, "numAtRisk": 28}]}, {"term": "Dysmenorrhoea", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 28}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 26}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 27}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 26}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 25}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 27}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 28}, {"groupId": "EG007", "numAffected": 2, "numAtRisk": 28}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 28}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 26}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 27}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 26}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 25}, {"groupId": "EG005", "numAffected": 2, "numAtRisk": 27}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 28}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 28}]}, {"term": "Vomiting", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 28}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 26}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 27}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 26}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 25}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 27}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 28}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 28}]}, {"term": "Red blood cell abnormality", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 28}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 26}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 27}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 26}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 25}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 27}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 28}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 28}]}, {"term": "Flatulence", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 28}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 26}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 27}, {"groupId": "EG003", "numAffected": 2, "numAtRisk": 26}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 25}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 27}, {"groupId": "EG006", "numAffected": 1, "numAtRisk": 28}, {"groupId": "EG007", "numAffected": 1, "numAtRisk": 28}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period \u226460 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication."}, "pointOfContact": {"title": "Boaz Hirschberg", "organization": "AstraZeneca Pharmaceuticals", "email": "ClinicalTrialTransparency@astrazeneca.com"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000003924", "term": "Diabetes Mellitus, Type 2"}], "ancestors": [{"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "relevance": "LOW"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "asFound": "Type 2 Diabetes Mellitus", "relevance": "HIGH"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000008687", "term": "Metformin"}, {"id": "C000502994", "term": "Saxagliptin"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000054795", "term": "Incretins"}, {"id": "D000006728", "term": "Hormones"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D000054873", "term": "Dipeptidyl-Peptidase IV Inhibitors"}, {"id": "D000011480", "term": "Protease Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M11667", "name": "Metformin", "asFound": "Assessment", "relevance": "HIGH"}, {"id": "M228152", "name": "Saxagliptin", "asFound": "Manufacturer", "relevance": "HIGH"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}, {"id": "M27905", "name": "Incretins", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}, {"id": "M27957", "name": "Dipeptidyl-Peptidase IV Inhibitors", "relevance": "LOW"}, {"id": "M19609", "name": "HIV Protease Inhibitors", "relevance": "LOW"}, {"id": "M14343", "name": "Protease Inhibitors", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "Infe", "name": "Anti-Infective Agents"}]}}, "hasResults": true}